低剂量氨鲁米特对绝经后乳腺癌患者外周芳香化作用的有效抑制
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
作者信息
Dowsett M, Santner S J, Santen R J, Jeffcoate S L, Smith I E
出版信息
Br J Cancer. 1985 Jul;52(1):31-5. doi: 10.1038/bjc.1985.144.
Abstract
Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1). The mechanism of action of this approach is thought to be the inhibition of peripheral aromatase, the enzyme which converts androstenedione to oestrone. The activity of this enzyme was measured in vivo by injection with 3H-androstenedione and 14C-oestrone and found to be 0.20% +/- 0.05 in 5 patients on low dose AG therapy. In comparison with previously published data this demonstrates a 92% inhibition of peripheral aromatase activity confirming aromatase inhibition as a viable aim in the endocrine treatment of breast cancer.
摘要
已证明，无糖皮质激素的氨鲁米特在低剂量（每日250毫克）时是绝经后乳腺癌的一种临床有效治疗方法。这种治疗方法的作用机制被认为是抑制外周芳香化酶，即一种将雄烯二酮转化为雌酮的酶。通过注射3H-雄烯二酮和14C-雌酮在体内测量该酶的活性，发现在接受低剂量氨鲁米特治疗的5名患者中，该酶活性为0.20%±0.05。与先前发表的数据相比，这表明外周芳香化酶活性受到92%的抑制，证实芳香化酶抑制是乳腺癌内分泌治疗的一个可行目标。
相似文献
1
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.低剂量氨鲁米特对绝经后乳腺癌患者外周芳香化作用的有效抑制
Br J Cancer. 1985 Jul;52(1):31-5. doi: 10.1038/bjc.1985.144.
2
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.低剂量氨鲁米特作为芳香化酶抑制剂治疗乳腺癌的内分泌效应
Clin Endocrinol (Oxf). 1985 Feb;22(2):219-26. doi: 10.1111/j.1365-2265.1985.tb01083.x.
3
Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.用于治疗乳腺癌的芳香化酶抑制剂：当前概念与新视角
Breast Cancer Res Treat. 1986;7 Suppl:S23-35.
4
The role of aromatase inhibitors in breast cancer.芳香化酶抑制剂在乳腺癌中的作用。
Semin Oncol. 1983 Dec;10(4 Suppl 4):20-4.
5
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.氨鲁米特作为一种芳香化酶抑制剂的体内和体外药理学研究。
Cancer Res. 1982 Aug;42(8 Suppl):3353s-3359s.
6
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.氨鲁米特及其类似物罗格列米特对乳腺癌外周芳香化作用的影响。
Br J Cancer. 1992 Oct;66(4):692-7. doi: 10.1038/bjc.1992.339.
7
Inhibition of androgen aromatization in human breast cancer.
J Steroid Biochem. 1980 Dec;13(12):1395-400. doi: 10.1016/0022-4731(80)90049-7.
8
Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.采用适用于体内评估芳香化酶抑制剂的尿液技术来测量芳香化作用。
J Enzyme Inhib. 1991;4(4):315-25. doi: 10.3109/14756369109030396.
9
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.低剂量氨鲁米特单药对晚期绝经后乳腺癌的内分泌作用
Br J Cancer. 1983 May;47(5):621-7. doi: 10.1038/bjc.1983.100.
10
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.低剂量氨鲁米特治疗绝经后乳腺癌：对肾上腺和甲状腺激素分泌的影响。
Eur J Cancer. 1991;27(7):846-9. doi: 10.1016/0277-5379(91)90131-v.
引用本文的文献
1
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.从结构-功能角度看新一代芳香化酶抑制剂发现的研究进展
J Med Chem. 2016 Jun 9;59(11):5131-48. doi: 10.1021/acs.jmedchem.5b01281. Epub 2016 Jan 19.
2
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.蛋白酶体抑制作用抑制 ER+ 细胞中 ERalpha 基因的表达：蛋白酶体活性与乳腺癌中雌激素信号之间的新联系。
Oncogene. 2010 Mar 11;29(10):1509-18. doi: 10.1038/onc.2009.434. Epub 2009 Nov 30.
3
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.4-羟基雄烯二酮与氨鲁米特联合治疗：对芳香化酶抑制及雌激素抑制的作用
Br J Cancer. 1994 Jun;69(6):1171-5. doi: 10.1038/bjc.1994.230.
4
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.接受4-羟基雄烯二酮治疗的乳腺癌患者的血浆和尿液雌激素
Br J Cancer. 1993 Aug;68(2):393-8. doi: 10.1038/bjc.1993.347.
5
Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.低剂量氨鲁米特对绝经后Ⅰ期乳腺癌患者自然杀伤细胞活性的调节作用
Cancer Immunol Immunother. 1987;24(1):72-5. doi: 10.1007/BF00199836.
6
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.氨鲁米特作为乳腺癌内分泌治疗的作用机制
Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.
7
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.低剂量氨鲁米特联合与不联合氢化可的松对绝经后乳腺癌患者内分泌影响的比较。
Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223.
8
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.氨鲁米特的酶诱导作用：药理学及内分泌学意义
Cancer Chemother Pharmacol. 1990;26(4):241-4. doi: 10.1007/BF02897223.
9
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.氨鲁米特治疗晚期乳腺癌：低剂量和高剂量后的血药浓度及临床结果
Cancer Chemother Pharmacol. 1991;27(6):451-5. doi: 10.1007/BF00685159.
10
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.CGS 16949A对乳腺癌患者外周芳香化作用的影响。
Br J Cancer. 1991 May;63(5):789-93. doi: 10.1038/bjc.1991.175.
本文引用的文献
1
Inhibition of androgen aromatization in human breast cancer.
J Steroid Biochem. 1980 Dec;13(12):1395-400. doi: 10.1016/0022-4731(80)90049-7.
2
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.氨鲁米特治疗晚期绝经后乳腺癌。
Cancer Res. 1982 Aug;42(8 Suppl):3405s-3408s.
3
Significance of aromatase activity in human breast cancer.芳香化酶活性在人类乳腺癌中的意义。
Cancer Res. 1982 Aug;42(8 Suppl):3365s-3368s.
4
A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.一项比较手术切除肾上腺与氨鲁米特加氢化可的松治疗晚期乳腺癌女性疗效的随机试验。
N Engl J Med. 1981 Sep 3;305(10):545-51. doi: 10.1056/NEJM198109033051003.
5
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.在使用氨鲁米特抑制雌激素治疗转移性乳腺癌期间雄激素分泌的保留情况。
J Clin Invest. 1980 Mar;65(3):602-12. doi: 10.1172/JCI109705.
6
Biological significance of aromatase activity in human breast tumors.人乳腺肿瘤中芳香化酶活性的生物学意义。
J Clin Endocrinol Metab. 1983 Dec;57(6):1125-8. doi: 10.1210/jcem-57-6-1125.
7
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.低剂量氨鲁米特单药对晚期绝经后乳腺癌的内分泌作用
Br J Cancer. 1983 May;47(5):621-7. doi: 10.1038/bjc.1983.100.
8
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.4-羟基雄烯二酮治疗绝经后晚期乳腺癌患者
Lancet. 1984 Dec 1;2(8414):1237-9. doi: 10.1016/s0140-6736(84)92795-8.
9
Low-dose aminoglutethimide in treatment of advanced breast cancer.低剂量氨鲁米特治疗晚期乳腺癌
Lancet. 1984 Sep 15;2(8403):604-7. doi: 10.1016/s0140-6736(84)90596-8.
10
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.会议记录：在晚期乳腺癌中使用氨鲁米特和地塞米松进行肾上腺切除术
Cancer. 1974 Feb;33(2):503-12. doi: 10.1002/1097-0142(197402)33:2<503::aid-cncr2820330227>3.0.co;2-l.
Zotero 插件